Field defects in progression to adenocarcinoma of the colon and esophagus
Full Text
Reprint PDF

Keywords

apoptosis resistance
barrett's esophagus
chromosome instability
colon cancer
field effects
ulcerative colitis

How to Cite

1.
Bernstein C, Bernstein H, Payne CM, Garewal H. Field defects in progression to adenocarcinoma of the colon and esophagus. Electron. J. Biotechnol. [Internet]. 2000 Dec. 15 [cited 2024 Dec. 22];3(3):0-. Available from: https://www.ejbiotechnology.info/index.php/ejbiotechnology/article/view/v3n3-1

Abstract

A field of defective tissue (field defect) appears to be an early stage in the progression to adenocarcinoma of both the colon and the esophagus. In both cases the field is comprised of cells characterized by resistance to induction of apoptosis, aberrant increased proliferation and genomic instability. Specific mutations and epimutations occur in both types of field. Also there is evidence for aberrant overexpression or underexpression of specific proteins. Most of these early molecular alterations appear to promote either enhanced apoptosis resistance, proliferation, or genomic instability. The molecular alterations that are present early are often, but not always, also present to an even greater degree in the cancer itself. Many of the important events in the development of colonic and esophageal adenocarcinoma first occur in tissues that are histologically neither dysplastic nor malignant. The identification of early molecular defects in morphologically normal appearing tissue is paramount in identifying subjects at high risk for cancer.

Full Text
Reprint PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.